Global Bacterial Infection Diseases Market, Types (Bacterial Skin Infections, Foodborne Bacterial Infections, Sexually Transmitted Bacterial Infections, Others), Treatment (Medication, Therapy, Others), Diagnosis (Blood Tests, Imaging Studies, Others), Route of Administration (Oral, Topical, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029
Market Analysis and Size
Infections caused by bacteria have a significant impact on human health. The disease can strike anywhere on the body, and it is produced either by the organism or by the body's reaction to its existence. Bacteria are spread to humans by air, water, food, and living vectors. Contact, airborne, droplet, vectors, and vehicular transmission are the most common mechanisms of bacterial transmission. Morbidity and mortality are dramatically reduced when preventive measures are used. Water treatment, animal and human immunization, personal hygiene, and safer sex practices are illustrations of such approaches. Antibiotic resistance is an increasing concern, necessitating careful usage of antibiotics.
Data Bridge Market Research analyses that the bacterial infection diseases market was valued at USD 72.0 billion in 2021 and is expected to reach USD 138.28 billion by 2029, registering a CAGR of 8.50% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Types (Bacterial Skin Infections, Foodborne Bacterial Infections, Sexually Transmitted Bacterial Infections, Others), Treatment (Medication, Therapy, Others), Diagnosis (Blood Tests, Imaging Studies, Others), Route of Administration (Oral, Topical, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Eli Lilly and Company (U.S.), AstraZeneca (U.K.), Novartis AG (Switzerland), Johnson & Johnson Private Limited (U.S.), Teva Pharmaceutical Industries Ltd. (Ireland), Merck & Co., Inc. (U.S.), Allergan (Ireland), Bausch Health Companies Inc. (Canada), Abbott (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Sanofi (France), Merck KGaA (Germany), Sun Pharmaceutical Industries Ltd. (India), Endo International plc (Ireland), Apotex Inc. (Canada), Amneal Pharmaceuticals LLC. (U.S.), Fresenius Kabi AG (Germany), Torrent Pharmaceuticals Ltd. (India)
|
|
Market Opportunities
|
|
Market Definition
A bacterial infection occurs when a dangerous bacteria strain multiplies on or within the body. Bacteria have the ability to infect any part of the human body. Pneumonia, meningitis, and food poisoning are just a handful of the diseases that dangerous bacteria can cause. Bacteria can be spherical (cocci), rod-shaped (bacilli), or helical (spirilla). Gram staining, bacterial culture with antibiotic sensitivity determination, and other techniques such as genetic analysis are used to identify bacterial strains and aid in the treatment. Bacterial infections can damage the throat, lungs, skin, bowels, and other body parts. Many are minor, but others are serious. Antibiotics can effectively treat the majority of bacterial diseases. They either destroy or prevent germs from growing. This enhances the immune system's ability to combat germs.
Bacterial Infection Diseases Market Dynamics
Drivers
- Rising prevalence of bacterial infection diseases
The rising prevalence of bacterial infection diseases is anticipated to expand the market's growth rate. Infectious disorders include lower respiratory infections, pneumonia, malaria, and tuberculosis are also driving market expansion. The rising disease burden is pressuring government and non-government organizations to invest in research and development activities and accelerate the development of novel antibiotics as well as supportive regulatory measures to speed up the approval process and research financing. For instance, BARDA has partnered with the government to support a number of companies in developing innovative infectious disease medicines.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of bacterial infection diseases market is the rising healthcare expenditure which helps in improving its infrastructure. Government policies all around the world are focusing on strengthening the healthcare system by boosting healthcare budgets and creating consistent policies. Governments all throughout the world are supporting the healthcare system. The world's healthcare system has benefited from increased healthcare spending. Developed economies, such as the U.S., U.K., Germany, and Canada, invest substantial money in healthcare. China, Korea, India, and Korea are among the growing economies that are expanding their healthcare spending.
Furthermore, a surging number of government initiatives to spread awareness and sedentary lifestyle will result in the expansion of bacterial infection diseases market. Along with this, rising level of disposable income and increased exposure to chemicals and pollutants will enhance the market's growth rate.
Opportunities
- Rise in R&D activities
The market's growth is fueled by a growing number of research activities to develop innovative treatments to treat infectious disorders. This will provide beneficial opportunities for the bacterial infection diseases market growth. According to Pew Charitable Trust around 41 promising compounds were being researched to treat serious bacterial infections in December 2019. 17 of the 41 investigational medications are in the third phase of clinical trials or have filed a New Drug Application for approval, and are anticipated to be commercialized within the forecast period of 2022-2029. Four new antibiotics were approved by the US Food and Drug Administration in the second half of 2019.
Moreover, the market's growth is fueled by investment to develop advanced technologies and increase the number of emerging markets. These factors will provide beneficial opportunities for the bacterial infection diseases market growth.
Restraints/Challenges
On the other hand, the high cost associated with the treatment will obstruct the growth rate of bacterial infection diseases market during the forecast period of 2022-2029. The patent expiry of branded drugs and introduction of generic drugs will challenge the bacterial infection diseases market. Additionally, lack of healthcare infrastructure in developing economies and the dearth of awareness among people will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.
This bacterial infection diseases market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the bacterial infection diseases market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Bacterial infection diseases market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Bacterial Infection Diseases Market
In order to contain the coronavirus outbreak, most of the world's main nations were compelled to go into lockdown. Since then, the pandemic has delayed the expansion of the healthcare sector and disrupted the supply chain. Furthermore, governments in many nations had imposed nationwide lockdowns to halt the spread of COVID-19. As a result of this predicament, most pharmaceutical companies worldwide are focusing on preserving their commerce and cash flow rather than investing in product development. Key players in the healthcare sector were also having difficulty running their plants and working at full capacity in order to meet their production targets. However, the bacterial infection diseases market is likely to improve as respective government bodies lifted the enforced lockdown restrictions. Various sectors are anticipated to rebound quickly post COVID-19 pandemic due to the wide number of applications they serve. As a result, the market is projected to stabilize in the future.
Global Bacterial Infection Diseases Market Scope
The bacterial infection diseases market is segmented on the basis of types, treatment, diagnosis, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Types
- Bacterial Skin Infections
- Foodborne Bacterial Infections
- Sexually Transmitted Infections
- Others
Treatment
- Medication
- B-lactam
- Quinolones
- Macrolides
- Tetracyclines
- Others
- Therapy
- Others
Diagnosis
- Blood Tests
- Imaging Studies
- Others
Route of Administration
- Oral
- Topical
- Parenteral
- Others
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Bacterial Infection Diseases Market Regional Analysis/Insights
The bacterial infection diseases market is analysed and market size insights and trends are provided by country, types, treatment, diagnosis, route of administration, end-users and distribution channel as referenced above.
The countries covered in the bacterial infection diseases market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the bacterial infection diseases market because of the rising healthcare expenditure and increasing patient population in this region. Additionally, the growing focus of major key players in research and development activities will further propel the market’s growth rate.
Asia-Pacific is expected to be the fastest-growing region during the forecast period of 2022-2029 due to increasing prevalence of bacterial infections and large number of generic manufacturer in this region. Also, development of healthcare infrastructure and rising government initiatives will further propel the market’s growth rate in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Bacterial Infection Diseases Market Share Analysis
The bacterial infection diseases market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to bacterial infection diseases market.
Some of the major players operating in the bacterial infection diseases market are:
- Eli Lilly and Company (U.S.)
- AstraZeneca (U.K.)
- Novartis AG (Switzerland)
- Johnson & Johnson Private Limited (U.S.)
- Teva Pharmaceutical Industries Ltd. (Ireland)
- Merck & Co., Inc. (U.S.)
- Allergan (Ireland)
- Bausch Health Companies Inc. (Canada)
- Abbott (U.S.)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Pfizer Inc. (U.S.)
- GlaxoSmithKline plc (U.K.)
- Sanofi (France)
- Merck KGaA (Germany)
- Sun Pharmaceutical Industries Ltd. (India)
- Endo International plc (Ireland)
- Apotex Inc. (Canada)
- Amneal Pharmaceuticals LLC. (U.S.)
- Fresenius Kabi AG (Germany)
- Torrent Pharmaceuticals Ltd. (India)
SKU-